EUVIMEDEUVIMED entdecken
Crossref

Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis

Mikako Tochigi, Shogo Shigeta, Muneaki Shimada, Shuko Miyahara, Junko Hasegawa-Minato, Yusuke Shibuya, Masumi Ishibashi, Chiaki Hashimoto, Hideki Tokunaga, Nobuo Yaegashi

The Tohoku Journal of Experimental Medicine · 2024

DOI: 10.1620/tjem.2023.j095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Tohoku Journal of Experimental Medicine, 2024. Verfasst von Mikako Tochigi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tohoku University School of Medicine. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Endometrial Neoplasms, Quinolines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A multi-kinase inhibitor, lenvatinib, plus an immune checkpoint inhibitor, pembrolizumab, became a viable therapeutic option for advanced or recurrent endometrial cancer in Japan by the end of 2021. The Japanese population has a relatively unique genetic background. Hence, the safety profile and effectiveness of lenvatinib plus pembrolizumab may differ between the Japanese and other populations. This single-center, retrospective study aimed to evaluate the treatment efficacy of lenvatinib plus pembrolizumab and the safety profile of the associated adverse events. The clinical records of 15 patients, who received lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer at the Tohoku University Hospital, were reviewed. Best overall response and disease control rates were 40.0% and 73.3%, respectively. Treatment was discontinued owing to disease progression and adverse events in six patients, respectively. As of the end of July 2023, treatment was ongoing in the remaining three patients. The median treatment and progression-free survival durations were 118 and 258 days, respectively. Relative dose intensity of lenvatinib was not positively associated with progression-free survival, neither during the first 4 weeks after treatment initiation nor during the entire treatment period. All patients experienced one or more adverse events, the most common of which were hypothyroidism (90%) and hypertension (83.3%). Among the 15 patients, 13 required lenvatinib dose reduction owing to adverse events. One patient developed grade 4 interstitial pneumonia requiring intensive care. Our results validate the short-term efficacy of lenvatinib plus pembrolizumab, and indicate that dose optimization of lenvatinib could be individualized without impairing efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsEndometrial NeoplasmsQuinolinesAntibodies, Monoclonal, HumanizedFemaleHumansRetrospective StudiesNeoplasm Recurrence, LocalPhenylurea Compounds

Stichwörter der Autor:innen

combination therapyendometrial cancerlenvatinibpembrolizumabrelative dose intensity

Substanzen

pembrolizumablenvatinibPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Tohoku University School of Medicine.
  • Tohoku University Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University.

Zitieren

APA

Tochigi, M., Shigeta, S., Shimada, M., Miyahara, S., Hasegawa-Minato, J., Shibuya, Y., Ishibashi, M., Hashimoto, C., Tokunaga, H., & Yaegashi, N. (2024). Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis. The Tohoku Journal of Experimental Medicine. https://doi.org/10.1620/tjem.2023.j095

Vancouver

Tochigi M, Shigeta S, Shimada M, Miyahara S, Hasegawa-Minato J, Shibuya Y, et al. Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis. The Tohoku Journal of Experimental Medicine. 2024. doi:10.1620/tjem.2023.j095

BibTeX
@article{Tochigi2024,
  author = {Tochigi, Mikako and Shigeta, Shogo and Shimada, Muneaki and Miyahara, Shuko and Hasegawa-Minato, Junko and Shibuya, Yusuke and Ishibashi, Masumi and Hashimoto, Chiaki and Tokunaga, Hideki and Yaegashi, Nobuo},
  title = {Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis},
  journal = {The Tohoku Journal of Experimental Medicine},
  year = {2024},
  doi = {10.1620/tjem.2023.j095}
}
Kostenlos starten →